{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T18:25:19Z","timestamp":1757701519480,"version":"3.37.3"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T00:00:00Z","timestamp":1579651200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T00:00:00Z","timestamp":1579651200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013170","name":"Ono Pharmaceutical","doi-asserted-by":"publisher","award":["None"],"award-info":[{"award-number":["None"]}],"id":[{"id":"10.13039\/501100013170","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Bone Miner Metab"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1007\/s00774-019-01077-x","type":"journal-article","created":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T06:03:23Z","timestamp":1579673003000},"page":"511-521","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Minodronate combined with alfacalcidol versus alfacalcidol alone for glucocorticoid-induced osteoporosis: a multicenter, randomized, comparative study"],"prefix":"10.1007","volume":"38","author":[{"given":"Satoshi","family":"Soen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiko","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsutomu","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiya","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sakae","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masako","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuo","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Hagino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Hirakawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshio","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,1,22]]},"reference":[{"key":"1077_CR1","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/S0889-8529(05)70017-7","volume":"27","author":"NE Lane","year":"1998","unstructured":"Lane NE, Lukert B (1998) The science and therapy of glucocorticoid-induced bone loss. Endocrinol Metab Clin North Am 27:465\u2013483","journal-title":"Endocrinol Metab Clin North Am"},{"key":"1077_CR2","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1097\/00002281-200107000-00015","volume":"13","author":"JA Clowes","year":"2001","unstructured":"Clowes JA, Peel N, Eastell R (2001) Glucocorticoid-induced osteoporosis. Curr Opin Rheumatol 13:326\u2013332","journal-title":"Curr Opin Rheumatol"},{"key":"1077_CR3","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s001980200108","volume":"13","author":"TP Van Staa","year":"2002","unstructured":"Van Staa TP, Leufkens HG, Cooper C (2002) The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 13:777\u2013787","journal-title":"Osteoporos Int"},{"key":"1077_CR4","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1359\/jbmr.2000.15.6.993","volume":"15","author":"TP Van Staa","year":"2000","unstructured":"Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C (2000) Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15:993\u20131000","journal-title":"J Bone Miner Res"},{"key":"1077_CR5","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s00774-004-0596-x","volume":"23","author":"H Nawata","year":"2005","unstructured":"Nawata H, Soen S, Takayanagi R, Tanaka I, Takaoka K, Fukunaga M, Matsumoto T, Suzuki Y, Tanaka H, Fujiwara S, Miki T, Sagawa A, Nishizawa Y, Seino Y (2005) Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research (2004). J Bone Miner Metab 23:105\u2013109","journal-title":"J Bone Miner Metab"},{"key":"1077_CR6","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1056\/NEJM199807303390502","volume":"339","author":"KG Saag","year":"1998","unstructured":"Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, Thamsborg G, Liberman UA, Delmas PD, Malice MP, Czachur M, Daifotis AG (1998) Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Eng J Med 339:292\u2013299","journal-title":"N Eng J Med"},{"key":"1077_CR7","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1002\/1529-0131(200101)44:1<202::AID-ANR27>3.0.CO;2-W","volume":"44","author":"JD Adachi","year":"2001","unstructured":"Adachi JD, Saag KG, Delmas PD, Liberman UA, Emkey RD et al (2001) Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids. Arthritis Rheum 44:202\u2013211","journal-title":"Arthritis Rheum"},{"key":"1077_CR8","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1002\/1529-0131(199911)42:11<2309::AID-ANR8>3.0.CO;2-K","volume":"42","author":"S Cohen","year":"1999","unstructured":"Cohen S, Levy RM, Kellaer M, Boling E, Emkey RD, Greenwald M, Zizic TM, Wallach S, Sewell KL, Lukert BP, Axelrod DW, Chines AA (1999) Risedronate therapy prevents cortirosteroid-induced bone loss. Arthritis Rheum 42:2309\u20132318","journal-title":"Arthritis Rheum"},{"key":"1077_CR9","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1359\/jbmr.2000.15.6.1006","volume":"15","author":"DM Reid","year":"2000","unstructured":"Reid DM, Hughes RA, Laan RF, Sacco-Gibson NA, Wenderoth DH, Adami S, Eusebio RA, Devogelaer JP (2000) Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. J Bone MIner Res 15:1006\u20131013","journal-title":"J Bone MIner Res"},{"key":"1077_CR10","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s002230001146","volume":"67","author":"S Wallach","year":"2000","unstructured":"Wallach S, Cohen S, Reid DM, Hughes RA, Hosking DJ, Laan RF, Doherty SM, Rosen C, Brown J, Barton I, Chines AA (2000) Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 67:277\u2013285","journal-title":"Calcif Tissue Int"},{"key":"1077_CR11","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s00198-004-1614-5","volume":"15","author":"RN De Nijs","year":"2004","unstructured":"De Nijs RN, Jacobs JW, Algra A, Lems WF, Bijlsma JW (2004) Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D(3) analogues: a review with meta-analysis of randomized controlled trials including organ transplantation studies. Osteoporos Int 15:589\u2013602","journal-title":"Osteoporos Int"},{"key":"1077_CR12","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1007\/s00198-008-0816-7","volume":"20","author":"T Matsumoto","year":"2009","unstructured":"Matsumoto T, Hagino H, Shiraki M, Fukunaga M, Nakano T, Takaoka K, Morii H, Ohashi Y, Nakamura T (2009) Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study. Osteoporos Int 20:1429\u20131437","journal-title":"Osteoporos Int"},{"key":"1077_CR13","unstructured":"Matsumoto T, Yamamoto K, Takeuchi T, Tanaka Y, Tanaka S, Nakano T, Ito M, Tomomitsu T, Hirakawa A, Soen S Eldecalcitol is more effective than alfacalcidol in increasing bone mineral density in patients with glucocorticoid-induced osteoporosis: a multicenter, randomized, open-label study (e-GLORIA). J Bone Miner Metab (Submitted)"},{"key":"1077_CR14","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","volume":"8","author":"HK Genant","year":"1993","unstructured":"Genant HK, Wu CY, van Kuijk C, Nevitt MC (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Metab 8:1137\u20131148","journal-title":"J Bone Miner Metab"},{"key":"1077_CR15","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1007\/s00774-013-0441-1","volume":"31","author":"S Mori","year":"2013","unstructured":"Mori S, Soen S, Hagino H, Nakano T, Ito M, Fujiwara S, Kato Y, Tokuhashi Y, Togawa D, Endo N, Sawaguchi T (2013) Committee for vertebral fracture evaluation. Justification criteria for vertebral fractures: year 2012 revision. J Bone Miner Metab 31:258\u2013261","journal-title":"J Bone Miner Metab"},{"key":"1077_CR16","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s00198-003-1425-0","volume":"14","author":"JD Ringe","year":"2003","unstructured":"Ringe JD, Dorst A, Faber H, Ibach K, Sorenson F (2003) Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study. Osteoporos Int 14:801\u2013807","journal-title":"Osteoporos Int"},{"key":"1077_CR17","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s00774-014-0586-6","volume":"32","author":"Y Suzuki","year":"2014","unstructured":"Suzuki Y, Nawata H, Soen S, Fujiwara S, Nakayama H, Tanaka I, Ozono K, Sagawa A, Takayanagi R, Tanaka H, Miki T, Masunari N, Tanaka Y (2014) Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research: 2014 update. J Bone Miner Metab 32:337\u2013350","journal-title":"J Bone Miner Metab"},{"key":"1077_CR18","doi-asserted-by":"crossref","unstructured":"Craig H, Mallinckrod, Peter W, Lane, Dan Schnell, Yahong Peng, James P. Mancuso (2008) Recommendations for the Primary analysis of continuous endpoints in longitudinal clinical trials. Therapeutic Innovation Regulatory Science https:\/\/doi.org\/10.1177\/009286150804200402","DOI":"10.1177\/009286150804200402"},{"key":"1077_CR19","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1007\/s00198-011-1782-z","volume":"23","author":"R Okazaki","year":"2012","unstructured":"Okazaki R, Hagino H, Ito M, Sone T, Nakamura T, Mizunuma H, Fukunaga M, Shiraki M, Nishizawa Y, Ohashi Y, Matsumoto T (2012) Efficacy and safety of monthly oral minodoronate in patients with involutional osteoporosis. Osteoporos Int 23:1737\u20131745","journal-title":"Osteoporos Int"},{"key":"1077_CR20","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.bone.2011.07.011","volume":"49","author":"T Matsumoto","year":"2011","unstructured":"Matsumoto T, Ito M, Hayashi Y, Hirota T, Tanigawara Y, Sone T, Fukunaga M, Shiraki M, Nakamura T (2011) A new active vitaminD3 analog, eldecalcitol, prevents the risk of osteoporotic fractures- A randomized, active comparator, double-blind study. Bone 49:605\u2013612","journal-title":"Bone"},{"key":"1077_CR21","unstructured":"Director, Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare. PFSB\/ELD Notification No.0707\u20131 (July 7, 2017) Guideline for Clinical Evaluation of Osteoporosis Agents (revised edition)"},{"key":"1077_CR22","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s00774-011-0332-2","volume":"30","author":"H Hagino","year":"2012","unstructured":"Hagino H, Shiraki M, Fukunaga M, Nakano T, Takaoka K, Ohashi Y, Nakamura T, Matsumoto T (2012) Three years of treatment with minodoronate in patients with postmenopausal osteoporosis. J Bone Miner Metab 30:439\u2013446","journal-title":"J Bone Miner Metab"},{"key":"1077_CR23","volume-title":"Guidelines for the use of bone metabolic markers in the diagnosis and treatment of osteoporosis","author":"Task Force Committee of bone metabolic markers, Japan Osteoporosis Society","year":"2018","unstructured":"Task Force Committee of bone metabolic markers, Japan Osteoporosis Society (2018) Guidelines for the use of bone metabolic markers in the diagnosis and treatment of osteoporosis, 2018th edn. Japan Osteoporosis Society, Tokyo","edition":"2018"}],"container-title":["Journal of Bone and Mineral Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-019-01077-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00774-019-01077-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-019-01077-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T00:40:48Z","timestamp":1611189648000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00774-019-01077-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,22]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["1077"],"URL":"https:\/\/doi.org\/10.1007\/s00774-019-01077-x","relation":{},"ISSN":["0914-8779","1435-5604"],"issn-type":[{"type":"print","value":"0914-8779"},{"type":"electronic","value":"1435-5604"}],"subject":[],"published":{"date-parts":[[2020,1,22]]},"assertion":[{"value":"6 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"S.S. has received consulting fees, speaking fees, and\/or honoraria from Asahi Kasei Pharma, Astellas, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly Japan, MSD, Ono, Pfizer, Takeda and Teijin Pharma. K.Y. has received speaking fees, and\/or honoraria from AbbVie, Astellas, AYUMI Pharma, Bristol-Myers Squibb, Chugai, Eisai, Janssen, Mitsubishi-Tanabe, Ono and UCB Japan. T.T. has received grants from Astellas, Chugai, Daiichi-Sankyo, Takeda, AbbVie, Asahi kasei Pharma., Mitsubishi-Tanabe, Pfizer, Eisai, AYUMI Pharma, Nipponkayaku., Novartis and Shionogi. Personal Fee from: Astellas, AbbVie, AYUMI Pharma, Eisai., Gilead Sciences, GlaxoSmithKline, Sanofi., Taiho, Mitsubishi-Tanabe, Diaichi-Sankyo, Chugai, Taisho Pharma, Eli Lilly Japan, Novartis, Boehringer-ingelheim, Nipponkayaku, Pfizer\u3001Bristol\u2013Myers Squibb, Janssen and UCB Japan. Y.T. has received speaking fees and\/or honoraria from Daiichi-Sankyo, Astellas, Chugai, Eli Lilly Japan, Pfizer, AbbVie, YL Biologics, Bristol-Myers Squibb, Takeda, Mitsubishi-Tanabe, Novartis, Eisai, Janssen, Teijin Pharma and has received research grants from Asahi kasei Pharma, Mitsubishi-Tanabe, Chugai, Takeda, Sanofi, Bristol-Myers Squibb, UCB Japan, Daiichi-Sankyo, Eisai and Ono. S.T. has received consulting fees, speaking fees, and\/or honoraria from Amgen Astellas Biopharma, Astellas, Asahi Kasei Pharma, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly Japan, Ono, Pfizer, Taisho Toyama Pharma and Teijin Pharma. M.I. has received consulting fees, speaking fees, honoraria, and\/or research funding from Chugai, Astellas, Asahi Kasei Pharma, Daiichi-Sankyo, Eli Lilly Japan, MSD, Ono and Pfizer. H.H. has received lecture fees or grants from Asahi Kasei Pharma, Astellas, Chugai, Eisai, Eli Lilly Japan, Mitsubishi -Tanabe, Mochida, Ono, Pfizer, Taisho Toyama, Takeda, Teijin Pharma, MSD and UCB. A.H. has received consulting fees, speaking fees, honoraria, and\/or research funding from Astellas, Ono and Teijin Pharma. T.M. has received consulting fees from Chugai, Amgen Astellas Biopharma, Teijin Pharma, Daiichi-Sankyo and Asahi Kasei Pharma.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}